Pfizer Inc. announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for the treatment of people with relapsed or refractory multiple myeloma (RRMM). Elranatamab is a B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb).
